EndoClot PHS
Commercial- Indications
- Gastrointestinal bleeding
Company intelligence / Profile preview
EndoClot Plus has developed and commercialized a proprietary polysaccharide-based hemostatic powder system and a starch-derived submucosal injection agent. These products have demonstrated excellent safety profiles and are used widely in GI endoscopy to control bleeding and facilitate lesion removal. The company’s technologies are FDA-cleared for use in the U.S. market as of 2020, with distribution partnerships expanding their reach across the U.S. and internationally.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on EndoClot Plus.